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Abstract
Tumors driven by activation of the transcription factor MYC
generally show oncogene addiction. However, the gene expres-
sion programs that depend upon sustained MYC activity remain
unknown. In this study, we employed a mouse model of liver
carcinoma driven by a reversible tet-MYC transgene, combined
with chromatin immunoprecipitation and gene expression pro-
ﬁling to identify MYC-dependent regulatory events. As previously
reported, MYC-expressing mice exhibited hepatoblastoma- and
hepatocellular carcinoma–like tumors, which regressed when
MYC expression was suppressed. We further show that cellular
transformation, and thus initiation of liver tumorigenesis, were
impaired in mice harboring a MYC mutant unable to associate
with the corepressor protein MIZ1 (ZBTB17). Notably, switching
off the oncogene in advanced carcinomas revealed that MYC was
required for the continuous activation and repression of distinct
sets of genes, constituting no more than half of all genes deregu-
lated during tumor progression and an even smaller subset of
all MYC-bound genes. Altogether, our data provide the ﬁrst
detailed analysis of a MYC-dependent transcriptional program
in a fully developed carcinoma and offer a guide to identifying the
critical effectors contributing to MYC-driven tumor maintenance.
Cancer Res; 76(12); 3463–72. 2016 AACR.
Introduction
Overexpression of the oncogenic transcription factor MYC is
frequently observed in human tumors (1), and analysis of mul-
tiple mouse models conﬁrmed MYC's fundamental impact on
tumorigenesis and tumor maintenance (2). MYC belongs to the
bHLH-LZ (basic helix-loop-helix leucine zipper) transcription
factor family and dimerizes with the bHLH-LZ partner Max to
bind DNA, with a preference for the E-box motif CACGTG, or
variants thereof. In cells, however, MYC interacts very promiscu-
ously with chromatin: if expressed at high enough levels, it can be
detected at virtually all active regulatory elements in the genome,
including promoters and distal enhancers, a phenomenon
dubbed "invasion" (3–8). Even in this setting, however, MYC
acts to up- and downregulate deﬁned subsets of all targeted loci
(5, 6, 8), its mere binding at any given locus being insufﬁcient to
predict gene regulation (reviewed in ref. 8). Altogether, the
principles underlying the speciﬁcity of MYC-driven transcription-
al responses remain largely unknown, and are likely to include
cell-, context- or promoter-dependent cues (9, 10).
Cellular transformation by MYC requires not only dimeriza-
tion with Max and DNA binding, mediated by its C-terminal
bHLH-LZ domain (11), but also the integrity of its N-terminal
region, which includes its transactivation domain (12). Through
this region, MYC can associate with a wide range of coregulatory
proteins and complexes, including histone modiﬁers, chromatin
remodelers, or regulators of RNA polymerase II (RNAPII) pro-
cessivity, such as the kinase complexes TFIIH and pTEF-B (13).
Hence, MYC is most likely to activate gene expression at multiple
levels, including RNAPII loading and elongation (14, 15), as well
as to impact cotranscriptional events such asmRNA capping (16).
Transcriptional repression by MYC remains to be understood
mechanistically, but requires the same N- and C-terminal termi-
nal domains of the protein (17). The best-characterized MYC
cofactor in this process is MIZ1, a zinc-ﬁnger protein involved in
the regulation of a large fraction (up to 40%) of MYC-repressed
genes (6, 18). The use of a MYC mutant speciﬁcally impaired in
MIZ1 binding (V394D, hereafterMYC-VD) revealed an important
role for this interaction in tumorigenesis, in particular, in the
thymus (19) and medulloblastoma (20). Hence, albeit the reg-
ulatory programs involved in each particular tumor type remain
to be fully characterized, activation and repression of transcrip-
tion by MYC are both likely to contribute to its oncogenic
function.
Over the last two decades, numerous studies have aimed at
proﬁling MYC-driven transcriptional programs, whether in cell
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lines or tumor models. In line with its biologic roles in either
normal or tumor cells, MYC has emerged as a central regulator of
growth-promoting processes, such as DNA replication, energy
production, ribosomal biogenesis, glucose and glutaminemetab-
olism, the biosynthesis of amino acids and nucleotides, and
others (8, 10, 21). Nonetheless, because of the aforementioned
limitations in discriminating functional from incidental DNA-
binding events in vivo (8), we are still lacking deﬁnitive identiﬁ-
cation of the genes that are directly regulated by MYC in tumor
progression and/or maintenance.
Here, we combined a LAPtTA transgene expressing a tetracy-
cline-controlled transactivator (tTA) in the liver, with either of two
tTA-regulated c-MYC transgenes, one encoding wild-type MYC,
the otherMYC-VD (19). Analogous to previous studies based on a
different transgenic founder (22, 23),MYC-expressingmice devel-
oped oncogene-addicted liver tumors that rapidly regressed upon
silencing of MYC expression by doxycycline. Expression proﬁling
in developing and regressing tumors allowed us to discriminate
secondary from primary, MYC-dependent regulatory events, the
latter including equivalent numbers (ca. 1,200-1,400) of MYC-
induced and repressed genes. As in other tissues (19, 24),MYC-VD
showed reduced tumorigenic potential relative to wild-type MYC
in the liver, owing to an essential role of theMYC/MIZ1interaction
in repression in tumor initiation.
Materials and Methods
Cell culture
Embryonal liver cells BNL CL.2 (ATCC TIB-73) and 3T9ﬂ/ﬂ
ﬁbroblasts (25, 26) were cultured in DMEM, supplemented
with 10% FBS, 2 mmol/L L-glutamine, and penicillin/strepto-
mycin. Primary fetal hepatoblasts (fHB) and immortalized
lines from C57/JHsd mice were puriﬁed (as described below)
on embryonic day E18.5 and cultured in DMEM supplemented
with 10% FBS, 2 mmol/L L-glutamine, and penicillin/strepto-
mycin as well as HGF (40 ng/mL, Peprotech), EGF (20 ng/mL,
Peprotech), and dexamethasone (1 mmol/L, Sigma). On day 3
after puriﬁcation, fHBs were infected with retroviruses encod-
ing shp53 or human MYC or MYC-VD. Upon immortalization,
cells were plated on regular culture plates in growth medium
lacking additional growth factors. Super-infection with
RASG12V was performed after immortalization.
For 5'-Bromo-2'Deoxyuridine (BrdUrd) stainings, 3T9ﬂ/ﬂ ﬁbro-
blasts were incubated for 15 minutes with 33 mmol/L of BrdUrd
(B9285, Sigma), ﬁxed, stained with antibodies targeting BrdUrd
(347580, Becton Dickinson), and FITC-conjugated donkey-anti-
mouse antibodies (715-095-150, Jackson Immuno Research).
Fluorescence signal intensity was acquired with a FACSCalibur
(BD Biosciences) and analyzed using the FlowJo software.
Cre-mediated deletion of the ﬂoxed c-MYC alleles in 3T9ﬂ/ﬂ
ﬁbroblasts was achieved by addition of 100 mg/mL of Tat-cre to
the culture medium (supplemented with 0.1% serum). After
incubation at 37C for 1 hour, 0.1 mmol/L of chloroquine
(Sigma) was added to the medium for an additional 1 hour.
Cells were washed with PBS and regular culture medium was
added for further cultivation.
Animal experiments
FVB mice transgenic for tet-MYC (termed TetO-Myc in the
original publication) were kindly provided by Martin Eilers
(Theodor Boveri Institute, W€urzburg, Germany; ref. 19). In a
model of T-cell lymphomagenesis, several tet-MYC-WT and
V394D (hereafter VD) founder lines have been tested (see Sup-
plementary Fig. S2A in ref. 19). In our study, we used the founder
line MYC-wt-1 (#3584) for tet-MYC-WT and MYC-VD-2 (#3557)
for tet-MYC-VD. LAPtTA transgenic mice on C57/Bl6 background
[B6.Cg-Tg(tTALap)5Bjd/J; Jackson laboratories] were subjected to
accelerated backcrossing into the FVB strain for at least 5 passages
until > 98.6% clean FVB background was reached. Double-trans-
genic offsprings (heterozygous for either transgene) were moni-
tored 3 times per week for tumor development. Mice were
sacriﬁced and scored for survival curves when moribund. Tumor
nodules or control liver tissue from age-matched littermates were
dissected and processed freshly or frozen and stored at 80C
until further analysis. To switch of transgene expression, doxycy-
cline was administered in the food ad libitum (Mucedola). To
avoid effects of the circadian rhythmon gene expression andDNA
binding, samples were taken at the same time of the day (between
10 and 12 am). Experiments involving animals were done in
accordancewith the Italian Laws (D.lgs. 26/2014), which enforces
Dir. 2010/63/EU (Directive 2010/63/EU of the European Parlia-
ment and of the Council of 22 September 2010 on the protection
of animals used for scientiﬁc purposes).
Computational analysis
Computational analyses of next-generation sequencing (NGS)
data were performed as described elsewhere (5), with few mod-
iﬁcationsmentioned below. Brieﬂy, ChIP-seq andRNA-seq librar-
ies were sequenced with the Illumina HiSeq 2000 to a read length
of 50 bp (ChIP-seq: single-end, RNA-seq: paired-end). Readswere
ﬁltered using the FASTX-Toolkit suite (http://hannonlab.cshl.
edu/fastx_toolkit/) and the read quality was assessed using the
FastQC application (www.bioinformatics.babraham.ac.uk/pro-
jects/fastqc). After removal of duplicated reads, unique ones were
mapped to the mouse refseq genome mm9.
ChIP-seq reads were aligned using the BWA aligner using
default settings. Peaks were called with the MACS2 software,
retaining only peaks with a P <1e5 (narrow peaks, such asMYC)
or <1e8 (broad peaks, such as RNAPol II, H3K4me3,H3K27ac).
Enrichment values were determined as log2(ChIPnrc – Inputnrc),
where ChIPnrc and Inputnrc are the normalized read counts (nrc)
in the regions of interest in the ChIP and in the corresponding
input sample.
RNA-seq reads were aligned with the TopHat aligner with
default parameters. Read counts were associated to exons using
the HTSeq software (http://www-huber.embl.de/users/anders/
HTSeq/doc/overview.html). The expression of a gene with more
than one isoform was determined as the mean of the expression
values across all of its isoforms. The expression of each transcript
was estimated as RPKM value (reads per kilobase per million
mapped exonic reads), deﬁned over exons alone. Differentially
expressed genes (DEG) were identiﬁed using the Bioconductor
package DESeq2. DEGs in this study were deﬁned as genes whose
associated q value (from the DESeq2 output) was lower than 0.01
andwhole log2 fold change was >1 or <(1).We considered only
protein-coding genes and considered them expressed if the RPKM
value was above 3 (average of biologic replicates) in at least one
experimental condition. As experimental conditions, we consid-
ered control liver (C), tet-MYC tumors before (T) or after (Toff)
short-term tet-MYC inactivation, or tet-MYC V394D tumors
(Tvd). This cut-off parameter resulted in approximately 11,900
expressed genes.
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Immunohistochemistry
Tissue was washed in PBS, ﬁxed in 4% (v/v) of paraformalde-
hyde at room temperature for at least 6 hours, washed in PBS, and
then stored in 70% EtOH at 4C until further processing. Tissue
was dehydrated with increasing concentrations of EtOH, embed-
ded in parafﬁn blocks, cut into 5-mm sections and mounted on
glass slides. Sections were dewaxed and rehydrated through an
ethanol scale, heated in citrate solution (BioGenex #HK086-9K)
in a water bath at 99C for 30 minutes for antigen unmasking,
washedonce inwater, and treatedwith 3%H2O2 for quenching of
endogenous peroxidases. Tissue sections were stained with the
following antibodies: MYC (Y69; Abcam, ab32072; 1:100) or E-
cadherin (ECCD-1; Life Technologies, 131800; 1:200). After
incubation with with primary antibodies, slides were washed
twice with TBS and then incubated with secondary antibodies
(Dako Cytomation Envision System Labelled Polymer-HRP) for
45 minutes. The signal was revealed with DAB peroxidase sub-
strate solution (Dako) for 2 to 10 minutes. Slides were ﬁnally
counterstained with hematoxylin, dehydrated through alcoholic
scale, and mounted with Eukitt (Bio-Optica). Images were
acquired with the Olympus BX51 upright microscope (software
NIS, Nikon).
Data availability and additional methods
ChIP-seq and RNAseq data have been submitted to the NCBI
GEO database with the accession number GSE76078. Further
methods can be found in Supplementary Information.
Results
Induction of hepatoblastomas and HCC-like tumors by MYC
To study the interplay betweenMYC activity, transcription, and
chromatin organization in liver tumors, we used a tet-MYC/
LAPtTA mouse model as originally described (Supplementary
Fig. S1A; refs. 22, 23) but based on two different c-MYC trans-
genes, tet-MYC-WT and tet-MYC-VD, the latter expressing the
MYC V394Dmutant defective inMIZ1 binding (19). As expected,
breeding of either of these tet-MYC strainswith LAPtTA animals in
the absence of doxycycline led to expression of the human c-MYC
mRNA in liver progenitor cells in utero in double-transgenic
embryos (Supplementary Fig. S1B).
We ﬁrst characterized tumor progression induced by wild-type
MYC: at embryonic day E18.5, double-transgenic tet-MYC-WT/
LAPtTA (dtg) embryos appeared phenotypically indistinguish-
able from control siblings (Supplementary Fig. S1C), retained a
normal liver architecture at the histologic level (data not shown),
but showed slightly increased liver sizes (Supplementary Fig. S1D
and S1E). By 6 weeks of age, tet-MYC-WT/LAPtTA mice showed a
gross increase in abdominal size and fully penetrant, gender-
independent development of multinodal liver tumors that
expressed high MYC levels (Fig. 1A–E and Supplementary Fig.
S1F). Closer histologic assessment revealed both epithelial hepa-
toblastoma and HCC-like tumors, conﬁrming previous observa-
tions (23, 27). Tumors stained positive for E-cadherin (Fig. 1E)
expressedmRNAs encodingmarkers of fetal progenitor cells, such
as Afp, Dlk1, Sall4 (Supplementary Fig. S1H), and contained
frequent mitotic and apoptotic cells (Supplementary Fig. S1G).
As previously reported, MYC-driven liver tumors showed full
oncogene addiction (23), as feeding tumor-bearing mice with
doxycycline-containing food rapidly suppressed MYC expression
(Fig. 1F) and induced tumor regression, with signiﬁcant decreases
in tumor mass within a week, and apparently normal livers and
healthy conditions within 3–4 weeks (Fig. 1G). In summary, tet-
MYC activation in utero caused a prenatal increase in liver size and
the fully penetrant development of MYC-dependent hepatoblas-
tomas by the age of 4–6 weeks.
On the basis of a distinct tet-MYC strain, but the same LAPtTA
transgene and experimental scheme used here, others reported
slower tumor development following MYC activation in utero
(22). The reasons for these differences may be partly genetic
(distinctMYC transgenes), partly environmental, but are beyond
the scope of this study.
MYC-induced liver tumorigenesis is impaired by the V394D
mutation
We then addressed whether the V394D mutation affected
MYC's oncogenic activity in the liver, as previously reported in
lymphomas (19). Relative to tet-MYC-WT, tet-MYC-VD animals
showed delayed tumorigenesis (Fig. 1B). Once formed, however,
MYC-WT- and MYC-VD–induced tumors appeared equally
aggressive, moribund animals showing comparable liver weights
(Fig. 1H) and tumor load (Supplementary Fig. S2A). Albeit
variable among individual tumors, wild-type and mutant MYC
were expressed within similar ranges, either as mRNA (Fig. 1I) or
protein (Supplementary Fig. S2B). As with MYC-WT, MYC-VD–
induced tumors showed no signiﬁcant gender differences (Sup-
plementary Fig. S2C) and expressed the fHB markers Afp, Dlk1,
Sall4 (Supplementary Fig. S2E) and E-cadherin (Fig. 1E). By
histologic analysis, MYC-VD showed the same tumor types as
MYC-WT, albeit with increased frequency of the HCC-like tumors
compared with hepatoblastoma (Supplementary Fig. S2E). As a
marker of apoptosis, we monitored PARP cleavage, revealing
variability among tumors, but no signiﬁcant difference between
the two MYC genotypes (Supplementary Fig. S2B).
To address MYC function at a pretumoral stage, we puriﬁed
LAPtTA/tet-MYC-WT and VD fHBs by magnetic cell sorting with
an E-cadherin antibody (28). RT-PCR analysis revealed similar
MYCmRNA levels in both populations (Supplementary Fig. S1B),
showing comparable activation of a MYC-induced gene
(Smpdl3b) but defective repression of Cdkn1a by MYC-VD, as
expected (Supplementary Fig. S2F; ref. 29). MYC-WT and MYC-
VD led to similar increases in the number of fetal hepatoblasts
recovered per embryo (Supplementary Fig. S2G), suggesting
equivalent proliferative activities. Both forms ofMYC also rescued
cell proliferation in mouse 3T9 ﬁbroblasts upon deletion of the
endogenous c-MYC gene (25), as shown by cell counting, BrdUrd
incorporation, and colony formation (Supplementary Fig. S3A–
S3C), conﬁrming that MYC-VD possesses an intact proliferative
ability.
To further confront the oncogenic potential of wild-type and
mutant MYC, we puriﬁed wild-type E18.5 hepatoblasts and
infected these cells with retroviruses expressing MYC-WT or
MYC-VD together with an shRNA targeting TP53, allowing us to
obtain immortalized cell lines that could be further transformed
by expression of oncogenic RASG12V (28). RASG12V was expressed
at similar levels and enhanced proliferation of cells with either
MYC-WT or MYC-VD (Supplementary Fig. S3D and S3E) but the
latter showed marked defects in cellular transformation, as
assayed either in vitro by sphere formation in methylcellulose
(Fig. 1J) or in vivo by subcutaneous tumor growth in CD1-nude
mice (Fig. 1K). We also expressed tamoxifen-responsive MYC-
ERTAM chimeras in the murine fetal liver progenitor cell line BNL
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CL.2: again, activation of either the WT or VD forms of MYC-
ERTAM caused a similar increase in proliferative potential (Sup-
plementary Fig. S3F). When cultured in semi-solid medium,
however, cells expressing the MYC-ER VD mutant showed a
marked decrease in sphere-forming ability relative to the MYC-
ER WT controls (Supplementary Fig. S3F). Remarkably, knock-
down of MIZ1 with either of two different shRNAs (#8 and #9)
decreased sphere-forming efﬁciency of MYC-ER WT to levels
comparable with those of MYC-ER VD, ablating the difference
between the two forms of MYC. Hence, the deﬁcit in cellular
transformation of VD mutant was entirely attributable to its
interaction with MIZ1 (29). Taken together, the above data
indicate that while retaining normal proliferative activity, MYC-
VD is defective in cellular transformation, affectingmost likely the
frequency of tumor initiation in vivo.
Short-term MYC inactivation in tumors allows distinction
between MYC-dependent and independent genes
Whencomparing transcriptomeproﬁles at steady state incontrol
and tumor tissue, changes in any given mRNA may follow either
from its direct transcriptional control by MYC, or from indirect
regulatory effects. To discriminate between those two scenarios, we
took advantage of our switchablemodel and determined RNA-seq
proﬁles in three conditions: control livers (C), tet-MYC-WT–
induced tumor nodules (T), and tumors 16 hours after tet-MYC-
WT shutdown by exposure to doxycycline-containing food (Toff).
Hierarchical clustering of RNA-seq data clearly separated the three
conditions, while samples within each group showed strong cor-
relations (Fig. 2A and B; Supplementary Table S1). As expected,
gene expression changes between the two main transitions, C!T
and T!Toff, were counter-correlated at the genome-wide level
(Supplementary Fig. S4A). However, Toff showed only a partial
recovery of the C pattern, remaining closer to T than to C (Fig. 2A–
C). Calling for differentially expressed genes (DEG, Supplementary
Fig. S4B; Supplementary Table S1) revealed that most of the MYC-
dependent genes in tumors (i.e., DEG in T!Toff) also scored
during tumorigenesis (C!T), although larger numbers ofDEGs in
C!T showed no MYC dependency in T!Toff (Fig 2C–E). In this
setting, MYC-dependent mRNAs most likely represented directly
regulated, primary target genes, whereas MYC-independent genes
weremost likely deregulated in tumors via secondarymechanisms.
Most importantly, the distinction between these two regulatory
categories was not a trivial consequence of differences in either
expression levels (Fig. 2F) or fold changes (Fig. 2G). The set of
primary induced targets enriched for genes involved in cell-cycle
progression,DNA, RNA, and protein biosynthesis (Supplementary
Fig. S4C; Supplementary Table S2), concordant with the observa-
tions in multiple models and with the general growth-promoting
activity of MYC (8, 10, 21).
To further validate the direct regulation of the primary target
genes identiﬁed in the tet-MYC model, we used a different
switchable KI mouse model that expresses elevated levels of
MYC-ERTAM in the liver (Pellegrinet and colleagues; manuscript
in preparation). RNA-seq analysis following short-term activation
(6 hours) of MYC-ERTAM revealed consistent responses of the
primary MYC-induced and repressed mRNAs previously deﬁned
in the T!Toff transition (categories 2, 3 and 5, 6, respectively;
Fig. 2H). Hence, switching MYC off in tumors and activating it in
thenormal liver revealed conservationof the direct transcriptional
responses in these two different states.
Altogether, most of the genes that were deregulated during
tumorigenesis showed no direct dependency upon MYC in
tumors, even though most of those genes are also bound by MYC
in their promoters (see below). Thus, more than DNA binding,
RNA-seq analysis following tet-MYC shutdown allowed narrow-
ing down on those genes that are primarily regulated by MYC
(Supplementary Table S1), and are thus the most likely to be its
direct effectors in tumor progression andmaintenance. These data
are also consistent with the notion that besides MYC-activated
genes, repressed genes may be as important in tumorigenesis (8,
30). Hereafter, we present data that directly address this notion.
Primary repression is selectively compromised in MYC-VD–
induced tumors
To address the transcriptional activity of MYC-VD, we estab-
lished RNA-seq proﬁles in the corresponding tumors and iden-
tiﬁed DEGs relative to control liver samples. Hierarchical cluster-
ing only partially discriminated WT- from VD-induced tumors
(hereafter T and Tvd; Fig. 3A), in line with the similar expression
proﬁles of those tumor populations (Fig. 3B). Consistentwith this
Figure 1.
tet-MYC-VD is impaired in liver tumor induction compared with tet-MYC-WT. A, representative photos of double-transgenic tet-MYC/LAPtTA mice upon tet-MYC
induction in utero, or single-transgenic tet-MYC control mice, showing the increased abdominal size in male and female double-transgenic mice by the
age of 6 weeks. B, Kaplan–Meier survival curve of tet-MYC-WT (orange) or tet-MYC-VD (green) overexpressing, or control (wild-type or single-transgenic, black)
mice. Mice were euthanized and scored when moribund. The median survival was 5 weeks for tet-MYC-WT and 13 weeks for tet-MYC-VD–expressing mice.
Signiﬁcance was assessed using the log-rank test. C, representative photo of a tet-MYC-WT–overexpressing liver containing multiple tumor nodules. D, mRNA and
Western blot analyses of human MYC mRNA (¼ transgene) and mouse/human MYC protein expression in control liver and tet-MYC-WT tumor samples. For
Western blot analyses, the MYC antibody Y69was used. It recognizes MYC of mouse and human origin. E, representative immunohistochemical stainings of control,
tet-MYC-WT, and tet-MYC-VD samples, using antibodies targeting MYC or E-cadherin. F, human MYC mRNA levels in control (C) livers or tet-MYC-WT
tumors before (T) or after (16 hours; Toff) doxycycline treatment were assessed by qRT-PCR. For Western blot analyses, the MYC antibody Y69 was used (see C).
G, photos of one tet-MYC-WT–expressing mouse at the age of 6 weeks before switching off tet-MYC transgene expression, displaying strong abdominal
swelling (left). Providing doxycycline food led to rapid regression of the tumors, as observable on the photos taken after 1 (middle) and3.5weeks (right) of treatment.
H, liver weight (in grams, g) of control (C), tet-MYC-WT (T), or tet-MYC-VD (Tvd) overexpressing mice on the day of euthanasia. Signiﬁcance was assessed
with the Student t test andP values are displayed in the ﬁgure or as follows: T vs. C, 4.6 1037; Tvd vs. C, 2.3 1037. I, qRT-PCR analyses of humanMYCmRNA levels
in tumors (T or Tvd) or control livers. The numbers in brackets originate from independent replicates per genotype. Signiﬁcance was assessed using the
Student t test. J and K, primary fHBs were puriﬁed from embryos on day E18.5 using anti-E-cadherin antibodies. Upon short-term in vitro culture, fHBs were infected
with shp53, MYC, and, where indicated, RASG12V. J, cellswere plated in triplicates in semisolidmedium [50%methylcellulose (v/v)] and cultured for 7 days. Datawere
normalized to plated cell numbers, measured by absorbance values of the MTT assay performed on parallel cultures 24 hours after plating. Signiﬁcance
was assessed with the Student t test. K, fHBs were injected into CD1-nude mice and tumor volumes were determined on the indicated days. The inset shows the
corresponding tumors on day 14.
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ﬁnding, either up- or downregulated genes in the C!T and
C!Tvd transitions were largely overlapping (Fig. 3C). Yet, an
important difference emerged when distinguishing among the
different regulatory modes previously identiﬁed on the basis of
the shut-off of tet-MYC-WT. In particular, secondary response
genes were similarly deregulated in C!T and C!Tvd, regardless
of whether they were induced or repressed (Fig 3D, i and ii). The
same was true for the primary MYC-induced genes (Fig 3D, iii),
conﬁrming that MYC-VD is as effective as WT in transcriptional
activation (18). Instead, primary MYC-repressed genes showed
weaker downregulation in C!Tvd relative to C!T (Fig 3D, iv):
among these, 285 genes were repressed with a 2-fold lower
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Figure 2.
RNA-seq analyses after short-term MYC inactivation identify MYC-dependent and MYC-independent DEG categories. A, hierarchical clustering (Spearman
correlation, method "complete") of RNA sequencing results of control liver samples (C, n¼ 11) and tet-MYC tumors before (T, n¼ 16) or after (Toff, n¼ 8) short-term
inactivation (16 hours) of the exogenous tet-MYC transgene. Samples originate from separate tumor nodules from a total of 11 C, 7 T, or 3 Toff mice. B,
cluster dendrogramof thehierarchical clustering (seeA). Sample identiﬁcation numbersof the biologic replicates are shown, includingaunique six-digit code and the
nodule name (deﬁned by letters, e.g., A–D). C, heatmap showing DEGs (from C!T) of C, T, and Toff samples. Shown are mRNA expression fold changes
relative to the average expression among all control liver replicates. D and E, Venn diagrams of MYC-induced (D) and repressed (E) genes. DEGs were
calculated comparing tumorswith control samples (C!T), or tumors after to before tet-MYC inactivation (T!Toff), the latter deﬁning the primary, MYC-dependent
DEG categories. The regulatory categories deﬁned here will be used throughout this work. F, violin plots depicting the expression levels (RPKM, log2)
of genes belonging to primary and secondary regulatory categories (seeD and E). G, box plots showing the expression fold changes (log2) of the different regulatory
categories, as indicated below the graphs. Comparisons were done at the control to tumor transition (C!T, top), or the transition from tumors before to
after Tet-MYC inactivation (T!Toff, bottom). H, box plot displaying expression fold changes (log2) of MYC target genes (identiﬁed in the tet-MYCmouse model) in
liver samples of adult mice expressing a TAM-inducible MYC-ER transgene. Samples were taken 6 hours after TAM injection.
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efﬁciency in MYC-VD relative to MYC-WT tumors (Fig. 3E; Sup-
plementary Table S3), enriching for functional categories includ-
ing cell adhesion/response to wounding (Fig. 3F), as previously
reported in different cellular compartments (18, 31).
Genomic MYC-binding proﬁles are not predictive of MYC-
dependent regulation
MYCassociateswith active promoters and enhancers in ahighly
promiscuous manner and up- or downregulates large, yet discrete
sets of genes, although no general rules have yet emerged con-
cerning the relationship between DNA binding and gene regula-
tion (8). To address this issue in our model, we used ChIP-seq
technology to determine the chromatin-binding proﬁles of MYC,
RNA polymerase II (RNAPII), and the active histone marks
H3K4me3 and H3K27ac. Focusing on annotated promoter
regions revealed a tight correlation between the presence of
RNAPII, H3K4me3, andH3K27ac (in either C, T, or Toff samples)
and MYC binding in T, while promoters lacking those features
remained unbound (Supplementary Fig. S5A–S5D).Most impor-
tantly, active promoter marks pre-existed in C and were retained
following MYC elimination in Toff. Thus, consistent with other
studies, overexpressed MYC in T widely associated with already
active promoters while inactive promoters remained unbound
(3–5, 7, 8).
MYC-binding proﬁles did not allow distinguishing primary
from secondary MYC-responsive genes, whether considering the
presence of a MYC peak at the promoter (Supplementary Fig.
S5E), its localization relative to the TSS (Supplementary Fig. S5F),
or binding intensities in control liver or tumors (Fig. 4A). Remark-
ably, relative to nonregulated genes, primary repressed genes
(categories 5, 6) were less frequently and more weakly bound,
and showed a lower frequency of E-boxes around their TSS, while
the opposite was true for primary induced genes (categories 2,
3; Fig. 4A and Supplementary Fig. S5G). These features were
conﬁrmed among MYC-ER–responsive genes in ﬁbroblasts (Sup-
plementary Fig. S5H; ref. 5). In tumors, overexpressed MYC
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associated with active promoters in a widespread manner, but
increases in binding neither discriminated MYC-dependent from
-independent transcriptional responses (Fig. 4B), nor correlated
with the extent of changes inmRNA levels (Fig. 4C). Furthermore,
neither MYC-binding nor recruitment to enhancers (determined
by nearest-neighbor analyses) in C or T discriminated primary
from secondary MYC target genes (Supplementary Fig. S5I and
S5J). Taken together, no simple rule could be drawn that would
link promoter/enhancer association by MYC with either primary
or secondary gene regulation.
MYC inﬂuences promoter-loading of RNA Pol II at both
activated and repressed loci
MYCwas suggested to regulate global RNA Pol II activity at the
elongation step (15), although other observations were inconsis-
tent with the generality of this effect (5, 8) and effects have also
been reported at the RNA Pol II loading step (14, 32). RNA Pol II–
binding intensities in the promoter regions of expressed genes
correlated well within C or T replicates, while larger variations
occurred during the C!T transition (Supplementary Fig. S6A).
Most importantly, up- or downregulation of gene expression was
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paralleled by equivalent changes in RNA Pol II binding at pro-
moters (Supplementary Fig. S6B). In particular, while during the
C!T transition, either primary or secondary genes (classes 2/5
and 1/4, respectively) showed similar variations in Pol II binding
(Fig. 4E), only primary MYC-dependent genes (classes 2,3/5,6)
were affected during the T!Toff transition (Fig. 4D and E). Thus,
MYC inﬂuences RNA Pol II loading on either activated or
repressed genes.
Transcription can be regulated at all steps of the RNA Pol II life
cycle, including loading, pausing, and elongation. To investigate
the relative contribution of these steps in our experimental
system, we calculated the RNA Pol II occupancy on promoters
and gene bodies, as well as their ratio, or stalling index (also
termed traveling ratio; refs. 15, 33) for the different regulatory
groups. Computing these values for the different regulatory
classes (Fig. 4F) showed consistent changes in Pol II abundance
not only on promoters, as mentioned above, but also on gene
bodies. However, stalling indices were not consistently affected in
any of the regulatory categories, conﬁrming this measure alone is
insufﬁcient in assessing RNA Pol II dynamics (5, 34). Altogether,
whether regulated by MYC in a primary or secondary manner,
activated and repressed genes showed generally consistent
changes in Pol II loading and elongation. Further studies will be
required to elucidate the contribution of each regulatory step to
MYC activity.
Discussion
The addiction of tumors to oncogenes such as c-MYC (2)
indicates that deregulated oncogenic signaling is continuously
required for tumor maintenance. Identifying the downstream
effectors of driving oncogenes in speciﬁc tumor types is thus an
importantmeans to narrow down on possible therapeutic targets.
Here, we proﬁled transcriptional responses in liver carcinomas
driven by a tetracycline-repressible tet-MYC transgene (19, 22). A
previous study based on an analogous model reported proﬁles
obtained 3 days after MYC shut-off (35): at this stage, however, a
number of indirect effects are likely to become predominant,
including apoptosis or differentiation into hepatocytes and bil-
iary cells (23). Using short-term inactivation of the transgene in
tumors (16 hours), we showed thatMYCwas directly required for
either activation or repression of distinct groups of genes (each
over 1,000 genes). TheseMYC-dependent genes represented close
to half of all those deregulated in tumors relative to normal tissue.
This difference was expected, as tumor transcriptomes are shaped
by a series of indirect effects, such as the deregulation of other
transcription factors, RNA-regulatory proteins, ormiRNAs, aswell
as changes in cellularmetabolism, differentiation state, andothers
(8, 10, 21). Thus, most importantly, our data allowed us to
discriminate between primary MYC-regulated targets and a pleth-
ora of secondary, indirect changes in gene expression.
Besides tet-MYC, we used tet-MYC-VD transgenic mice,
encoding a mutant defective in binding to the corepressor
MIZ1. As in other tissues (19, 24), tet-MYC-VD in the liver
showed signiﬁcantly reduced tumorigenic potential relative to
wild-type MYC. Expression proﬁling of MYC-VD–driven
tumors showed a selective impairment in the downregulation
of a subset of the primary MYC-repressed genes identiﬁed upon
tet-MYC shut down. Hence, MIZ1-dependent repression plays
an important role in MYC-induced liver tumorigenesis. In line
with the fact that MYC-repressed transcriptional programs
appear to be largely tissue-speciﬁc, the requirement for the
MYC-MIZ1 interaction appears to differ among the tumor types
studied so far, including suppression of TGFb-mediated senes-
cence in T-cell lymphomas (19), maintenance of stemness in
medulloblastoma (24) and, possibly related to the latter, tumor
initiation in the liver (this work).
Altogether, the data presented in this and previous work (5, 6,
8) show that only a fraction of the MYC-bound genes are deregu-
lated during tumorigenesis, with molecular determinants that
largely remain to be understood (8). In turn, as shown here, only
about half of these deregulated genes (whether activated or
repressed) show dependency upon MYC in tumors and may thus
represent direct regulatory targets: others may be deregulated
through indirect mechanisms or, alternatively, may be expressed
in inﬁltrating cells, such as lymphocytes or leukocytes, as also
suggested by gene ontologies (Supplementary Fig. S4C). Most
noteworthy in this regard, MYC may directly modulate the
expression of molecules that control the recruitment/activation
of immune cells: CD47 and PD-L1 (CD274), for example, were
recently reported to be downregulated upon tet-MYC inactivation
in either liver tumors or lymphomas, contributing to tumor
clearance in the latter (36). The generality of this mechanism
remains to be evaluated, however, as CD47 and CD274 were
slightly upregulated upon MYC inactivation in our liver model
(Supplementary Table S1).
Consistent with previous studies, MYC-activated genes were
particularly enriched for molecules involved in cell-cycle pro-
gression, proliferation, DNA and RNA biology (Supplementary
Fig. S4C; Supplementary Table S2; refs. 8, 21). Functional
screens will be instrumental in determining which of these
direct regulatory targets are essential effectors of MYC in tumor
maintenance, and may thus become the focus of future ther-
apeutic development.
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